An estimated 1.6 million adults in Great Britain used a GLP-1 or dual GLP-1/GIP medicine for weight loss in the year to early 2025. The MHRA has strengthened UK product information for these medicines twice since January 2026. Despite that scale of use, the evidence...
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...
Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...
Bristol Myers Squibb announced on 20 July 2026 that it will deploy an NVIDIA DGX SuperPOD built on eight DGX Vera Rubin NVL72 systems, a move the company says will give it the most powerful and energy efficient single-owned NVIDIA infrastructure in the life sciences...
IgA nephropathy, the most common primary glomerulonephritis worldwide, has undergone a remarkable transformation in its treatment landscape. Once managed solely with supportive care and immunosuppression of uncertain benefit, the IgA nephropathy drug pipeline now...
In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23...
Novo Nordisk and Aspect Biosystems expand collaboration to accelerate curative diabetes therapies The landscape of regenerative medicine has shifted significantly following the announcement that Novo Nordisk and Aspect Biosystems are entering a comprehensive new phase...
GSK has agreed to acquire US biotech company RAPT Therapeutics in a deal valued at approximately 2.2 billion US dollars, strengthening its position in immunology and signalling a major push into the emerging food allergy treatment market. The acquisition centres on...
We all know or work with people who can be difficult to deal with and even talk to, and we all know or work with other people who are a joy to be around and who make the working day a little brighter. Some of those difficult people will be highly competent in their...
Metformin has been the first line drug treatment for type 2 diabetes for more than two decades and remains one of the most widely prescribed medicines globally. Its effectiveness, low cost and long safety record have made it a cornerstone of diabetes care. However, as...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Johnson & Johnson has discontinued development of an eczema treatment that was a central asset in a biotechnology acquisition valued at up to 1.25 billion US dollars, following a recent internal portfolio review. The decision highlights the ongoing scientific and...
Concerns are mounting that the United Kingdom’s official appraisal framework is systematically underestimating the economic and social value of investments in life sciences manufacturing. Industry bodies and independent analysts warn that the methods used to evaluate...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...
Manufacturing and supply chain resilience has moved to the forefront of strategic planning across the life sciences industry as advanced therapies place unprecedented strain on existing production models. Cell therapies, gene therapies, mRNA platforms and increasingly...
Henry Li’s BioRoundup is a weekly analytical roundup that tracks where power, capital and science are actually moving in the global life-sciences ecosystem. Rather than simply reporting news headlines, Li curates developments from across deals, policy, industry...